

**SNCA Antibody (C-term) Blocking peptide**  
**Synthetic peptide**  
**Catalog # BP2955b****Specification**

---

**SNCA Antibody (C-term) Blocking peptide - Product Information**Primary Accession [P37840](#)**SNCA Antibody (C-term) Blocking peptide - Additional Information****Gene ID** 6622**Other Names**

Alpha-synuclein, Non-A beta component of AD amyloid, Non-A4 component of amyloid precursor, NACP, SNCA, NACP, PARK1

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP2955b](/products/AP2955b) was selected from the C-term region of human SYUA. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**SNCA Antibody (C-term) Blocking peptide - Protein Information****Name** SNCA**Synonyms** NACP, PARK1**Function**

Neuronal protein that plays several roles in synaptic activity such as regulation of synaptic vesicle trafficking and subsequent neurotransmitter release (PubMed: [28288128](http://www.uniprot.org/citations/28288128), PubMed: [30404828](http://www.uniprot.org/citations/30404828), PubMed: [20798282](http://www.uniprot.org/citations/20798282), PubMed: [26442590](http://www.uniprot.org/citations/26442590)). Participates as a monomer in synaptic vesicle exocytosis by enhancing vesicle priming, fusion and dilation of exocytotic fusion pores (PubMed: [28288128](http://www.uniprot.org/citations/28288128), PubMed: [30404828](http://www.uniprot.org/citations/30404828)

target="\_blank">30404828</a>). Mechanistically, acts by increasing local Ca(2+) release from microdomains which is essential for the enhancement of ATP-induced exocytosis (PubMed:<a href="http://www.uniprot.org/citations/30404828" target="\_blank">30404828</a>). Acts also as a molecular chaperone in its multimeric membrane-bound state, assisting in the folding of synaptic fusion components called SNAREs (Soluble NSF Attachment Protein REceptors) at presynaptic plasma membrane in conjunction with cysteine string protein-alpha/DNAJC5 (PubMed:<a href="http://www.uniprot.org/citations/20798282" target="\_blank">20798282</a>). This chaperone activity is important to sustain normal SNARE-complex assembly during aging (PubMed:<a href="http://www.uniprot.org/citations/20798282" target="\_blank">20798282</a>). Also plays a role in the regulation of the dopamine neurotransmission by associating with the dopamine transporter (DAT1) and thereby modulating its activity (PubMed:<a href="http://www.uniprot.org/citations/26442590" target="\_blank">26442590</a>).

#### **Cellular Location**

Cytoplasm. Membrane. Nucleus. Synapse Secreted. Cell projection, axon {ECO:0000250|UniProtKB:O55042}. Note=Membrane-bound in dopaminergic neurons (PubMed:15282274). Expressed and colocalized with SEPTIN4 in dopaminergic axon terminals, especially at the varicosities (By similarity). {ECO:0000250|UniProtKB:O55042, ECO:0000269|PubMed:15282274}

#### **Tissue Location**

Highly expressed in presynaptic terminals in the central nervous system. Expressed principally in brain

### **SNCA Antibody (C-term) Blocking peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

### **SNCA Antibody (C-term) Blocking peptide - Images**

### **SNCA Antibody (C-term) Blocking peptide - Background**

Alpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of patients with Alzheimer's disease.

### **SNCA Antibody (C-term) Blocking peptide - References**

Spillantini,M.G., et.al., Genomics 27 (2), 379-381 (1995)Chen,X., et.al., Genomics 26 (2), 425-427 (1995)